In brief
- A Sydney forensic team reviewed 217 MDMA-related deaths recorded in Australia between 2016 and 2025.
- The mortality rate rose sharply until 2019 and subsequently fell by approximately 27% annually through 2023.
- In 82.5% of cases, the official cause was polydrug toxicity, rather than MDMA alone.
A study published in the journal Addiction reviews a decade of autopsies and toxicological analyses linked to MDMA in Australia. Its authors, from the National Drug and Alcohol Research Centre at the University of New South Wales, did not find evidence of an increasingly lethal substance, but rather a pattern of consumption that rarely involves MDMA alone.
Ten years of forensic data
The team led by Shane Darke reviewed Australia’s National Coronial Information System and identified 217 deaths where MDMA was listed as a cause or contributing factor between 2016 and 2025. The rate of cases per capita rose sharply between 2016 and 2019 (an annual increase of 61.5%) and then fell with equal intensity through 2023 (an annual decrease of 26.7%).
Who dies and under what circumstances
The profile of the cases remained largely consistent throughout the decade studied. The average age was 33.5 years, and 78.3% were male. Most deaths, 78.8%, occurred in private residences; only 7.4% took place at music festivals, the setting typically associated with MDMA in the public imagination. The study’s central finding is clear: in 82.5% of cases, the cause of death was classified as polydrug toxicity, with other psychoactive substances detected in 91.7% of the bodies analyzed, primarily other stimulants (67.7%) and opioids (45.2%). When death was attributed solely to MDMA, the median blood concentration was significantly higher than in polydrug cases (1.7 mg/l versus 0.30 mg/l), suggesting that mixing substances can be lethal even with relatively low levels of MDMA. In bodies where the heart was examined, 16.6% showed cardiomegaly and 13.6% showed severe coronary artery disease.
What it implies
The study does not describe an increasingly dangerous MDMA supply: the characteristics of the cases remained stable across the pre-pandemic period, the COVID years, and the subsequent period, with no significant differences in age, sex, injection drug use, intent, or substance concentration. What is clear is that most deaths attributed to MDMA are not deaths from MDMA alone, but from combinations with opioids or other stimulants. From a harm reduction perspective, the practical takeaway is clear: knowing the composition of what you are taking and avoiding blind mixing is more critical than the dose of MDMA itself. In Spain, services like Energy Control have spent years detecting adulterants in pills sold as MDMA, and the same principle they advocate—testing before consumption and not combining substances without information—aligns with the findings of this Australian study based on ten years of autopsies.
Source
- Darke S, Duflou J, Chrzanowska A, Farrell M, Lappin J, Peacock A. Methylenedioxymethamphetamine (MDMA)-related fatal poisoning in Australia, 2016 to 2025: Trends, characteristics and toxicology. Addiction, September 21, 2026 (PMID 42767268).
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
